ArticleProceedings of the National Academy of Sciences of the United States of America2011
Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 59 citations in OpenAlex.
- The C-terminal truncated splicing variant of NK1R negatively modulates substance P-stimulated NK1R signaling.FEBS open bio · 2026Article
- Alternative Splicing at the Crossroad of Inflammatory Bowel Diseases and Colitis-Associated Colon Cancer.Cancers · 2025Review
- The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.Current medicinal chemistry · 2024Review
- Association of Neurokinin-1 Receptor Signaling Pathways with Cancer.Current medicinal chemistry · 2024Review
- Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor.Oncology reports · 2023Article
- Modulating the tachykinin: Role of substance P and neurokinin receptor expression in ocular surface disorders.The ocular surface · 2022Review
- Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.Molecular biology reports · 2022Article
- The Neurokinin-1 Receptor Is a Target in Pediatric Rhabdoid Tumors.Current oncology (Toronto, Ont.) · 2021Article
- A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?Cancers · 2020Review
- The substance P and neurokinin-1 receptor system in human thyroid cancer: an immunohistochemical study.European journal of histochemistry : EJH · 2020Article
- Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.Investigational new drugs · 2019Article
- MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis.Cell proliferation · 2019Article
- Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis.Journal of immunology (Baltimore, Md. : 1950) · 2017Review
- Difference in expression of two neurokinin-1 receptors in adenoma and carcinoma from patients that underwent radical surgery for colorectal carcinoma.Oncology letters · 2017Article
- PanIN Neuroendocrine Cells Promote Tumorigenesis via Neuronal Cross-talk.Cancer research · 2017Article
- Transforming Growth Factor Beta 1 Modulates the Functional Expression of the Neurokinin-1 Receptor in Human Keratocytes.Current eye research · 2016Article
- Truncated neurokinin-1 receptor is an ubiquitous antitumor target in hepatoblastoma, and its expression is independent of tumor biology and stage.Oncology letters · 2016Article
- The Therapeutic Potential of Targeting Substance P/NK-1R Interactions in Inflammatory CNS Disorders.Frontiers in cellular neuroscience · 2016Review
- Alternative Splicing of G Protein-Coupled Receptors: Relevance to Pain Management.Mayo Clinic proceedings · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Patients with chronic ulcerative colitis (UC) are at high risk for developing colorectal cancer. In this study, archival formalin-fixed paraffin-embedded colonic tissue from patients with UC who developed carcinoma (CA) or high-grade dysplasia (HGD) was examined for changes in expression of the proinflammatory and mitogenic neurokinin-1 receptor (NK-1R). Laser capture microscopy was used to microdissect epithelia from areas of colons that showed histologic evidence of CA, HGD, and epithelia that were not dysplastic or cancerous but did contain evidence of prior inflammation (quiescent colitis). mRNA was extracted from the dissected tissue, and PCR array analysis was performed on extracted mRNA. Two antibodies were necessary to separately estimate the protein levels of the truncated (tr-NK-1R) and full-length (fl-NK-1R) receptors by immunohistochemistry. mRNA expression of tr-NK-1R increased 14-fold (P = 0.02) when comparing the HGD and CA groups. In contrast, the fl-NK-1R transcript showed no significant differences among groups. The protein levels of the total NK-1R increased by 40% (P = 0.02) in HGD and 80% (P = 0.0007) in CA compared with quiescent colitis. There were no significant changes in protein levels of the fl-NK-1R. We conclude that the increase in total NK-1R protein in HGD and CA is attributable to an increase in tr-NK-1R, suggesting there may be a functional role for tr-NK-1R in malignant transformation in colitis-associated cancer. The tr-NK-1R could prove useful as a diagnostic marker to identify patients at risk for neoplasia and may serve as a useful therapeutic target in the treatment of colitis-associated cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.